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Iodinated Cyanine Dyes: A New Class of Sensitisers for 
use in NIR Activated Photodynamic Therapy (PDT)†   
Jordan Atchison1, Sukanta Kamila1, Heather Nesbitt1, Kieran A. Logan1, Dean M 
Nicholas1, Colin Fowley1, James Davis2, Bridgeen Callan1, Anthony P McHale1 and 
John F Callan1*
A new class of iodinated cyanine dyes have been prepared for 
use in NIR excited photodynamic therapy (PDT) and 
demonstrated improved efficacy in three pancreatic cell lines 
as well as excellent tumour control in a murine model of the 
disease. 
Photodynamic therapy (PDT) involves the pre-treatment of a 
cancerous lesion(s) with an otherwise inactive photosensitising drug 
that sensitises the tissue to light. Upon light activation, the drug 
undergoes a series of photochemical reactions that generate toxic 
quantities of reactive oxygen species (ROS) resulting in cell death.1  
The main attraction of using PDT as an anti-cancer treatment is that 
ROS generation can be controlled by exposing only target tissues to 
light, thereby limiting undesirable off-target toxic effects to normal 
tissue.2 The life-time and diffusion distance of ROS are also extremely 
short, meaning cellular damage is largely confined to the site of ROS 
generation.2 While PDT has proven effective for the treatment of 
superficial lesions, its ability to treat larger or more deeply-seated 
tumours is hampered by the inability of visible light to penetrate 
deeply through human tissue. As tissue attenuation is inversely related 
to the wavelength of light, longer wavelength light penetrates much 
deeper through human tissue than shorter wavelength light.3 Indeed, 
the phototherapeutic window, where tissue has maximum 
transparency to light, is in the near infrared (NIR) region between 750-
900 nm.3-5 At these wavelengths light is less prone to being filtered by 
other endogenous chromophores and as a result penetrates much 
deeper through living tissue. It is no surprise, therefore, that a 
significant body of work has focussed on developing new 
photosensitisers with absorption maxima in the phototherapeutic 
window, in an attempt to widen the applicability of PDT.4,6,7 
Indocyanine green (ICG), also referred to as Cardio Green, is a 
widely used NIR fluorophore that gained clinical acceptability in the 
early 1950’s.8 ICG has also been explored as a potential 
photosensitiser but an extremely low singlet oxygen quantum yield ( 
= 0.077) has limited its practical utility.9  Singlet oxygen generation 
in PDT involves energy transfer from the sensitisers excited triplet 
state to the ground state of molecular oxygen.  Excited triplet states 
are formed from excited singlet states via a process known as 
intersystem crossing (ISC).1,10 As fluorescence occurs as a result of 
radiative deactivation from a fluorophores excited singlet state, the 
fluorescence and singlet oxygen quantum yields are invariably linked, 
with good fluorophores typically being poor sensitisers and vice 
versa.11,12 Addition of heavy atoms to the structural skeleton of 
conjugated aromatics is known to increase the ISC process and 
improve singlet oxygen generation.7,13 Naturally, this usually comes 
at a price of reduced fluorescence emission. In this manuscript, we 
modify the structure of a basic cyanine dye by substituting hydrogen 
atoms with iodine atoms. The effect of these structural modifications 
on the compound’s absorption and fluorescence properties as well as 
their singlet oxygen generating potential was determined. 
Furthermore, the NIR activated PDT efficacy of the iodinated 
analogues is also established in two pancreatic cancer cell lines 
(BxPC-3 and MIA-PaCa-2) and in an in vivo murine model of the 
disease.  
IR-783 is a commercially available NIR cyanine dye with similar 
absorption and emission properties to ICG but has a modified 
chemical structure.14 We prepared two iodinated derivatives of IR-
783, where each indole ring was either mono-iodinated (6a) or di-
iodinated (6b) (Scheme 1). In the case of 6a, this involved first 
forming the diazonium salt of 4-iodoaniline (1a) followed by 
reduction using SnCl2 / NaBH4 to afford the hydrazine (2a). This was 
then refluxed with 3-methyl-2-butanone to produce the indole 3a, 
which after N-alkylation with 1,4-butane-sultone resulted in the 
formation of sulfonic acid derivative 4a. In parallel, compound 5 was 
prepared by a Vilsmeier-Haack reaction involving cyclohexanone, 
phosphoryl chloride and dimethylformamide. Compounds 4a and 5 
were then coupled together in a 1:2 molar ratio to produce target 
compound 6a. In the case of 6b, the precursor compound 3, 5-
diiodoaniline (1b) was prepared according to a literature procedure.15  
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The same series of reactions used to furnish 6a from 1a were also used 
to generate 6b from 1b. 
The effect of iodination on the photophysical properties of 6a 
and 6b was determined by studying their UV-Vis and fluorescence 
spectra in aqueous solution. For comparative purposes, the UV-Vis 
and fluorescence spectra of ICG were also recorded.16 The results are 
shown in fig S7a and reveal that ICG and 6a have similar absorption 
MAX values (780 and 790 nm respectively). In contrast, the UV-Vis 
spectrum of 6b was much broader with a significantly blue shifted 
MAX value (687 nm). The fluorescence spectra, recorded after 
excitation at 775 nm for ICG and 6a, and 687 nm for 6b, revealed a 
significantly quenched emission for 6b (f = 0.009) when compared 
to either ICG (f = 0.27) or 6a (f = 0.22) (fig S7b). Therefore, these 
results indicate that the number and/or position of iodine atom 
substitution on the indole ring of indocyanine dyes dramatically 
affects the photophysical properties of the resulting compounds with 
increasing iodination producing more dramatic effects on the UV-Vis 
and fluorescence spectra. 
  To determine the ability of 6a and 6b to generate singlet oxygen 
upon NIR excitation, the fluorescent probe Singlet Oxygen Sensor 
Green (SOSG) was utilised.17 SOSG is non-fluorescent in its reduced 
form but reacts specifically with singlet oxygen to generate a 
fluorescent product. The intensity of the fluorescence signal at 525 nm 
is indicative of the amount of singlet oxygen generated. PBS solutions 
containing SOSG and matched concentrations of either ICG, 6a or 6b 
were prepared and irradiated with 780 nm light (100 mW). The 
fluorescence intensity of the solutions at 525 nm was recorded before 
and 10 min after irradiation. A control experiment involving light 
irradiation of SOSG alone (i.e. no sensitiser) was also undertaken for 
comparative purposes. The results are shown in fig S8 and reveal 
significantly enhanced singlet oxygen generation for both 6a (7.9 fold, 
1O2 = 0.66) and 6b (4.4 fold, 1O2 = 0.44) relative to ICG. The 
increased singlet oxygen generation for 6a compared to 6b was 
surprising given the significantly reduced emission observed for the 
latter.  
To investigate if the improved 1O2 generation of 6a and 6b with 
respect to ICG would manifest itself in enhanced cellular toxicity, two 
pancreatic cancer cell lines (BxPC-3 and MIA PaCa-2) were seeded 
in 384 well plates and incubated with increasing concentrations (0-50 
µM) of the three compounds for 3 hours. Selected wells were then 
exposed to 780 nm light (100 mW) for 1 min and incubated in fresh 
media for a further 24 hr before cell viability was determined using a 
MTT assay. Cells incubated with either ICG, 6a or 6b alone (i.e. no 
light treatment) and cells exposed to light treatment alone (i.e. no 
drug) were also undertaken as controls. The results are shown in fig 1 
and reveal no noticeable PDT mediated reduction in cell viability for 
ICG in either cell line over the concentration range tested. In contrast, 
a dose-dependent PDT mediated reduction in cell viability was 
observed for 6a and 6b in both cell lines.  Interestingly, the effect was 
more dramatic in the MIA PaCa-2 cell line with less than 10% viable 
cells remaining at 50 µM drug concentration while the value was 
approximately 40% for BxPc-3 at the same concentration. While there 
was no significant difference between the efficacy of 6a or 6b in the 
BxPC-3 cell line, 6a proved more potent in the MIA PaCa-2 cell line 
with 10.2, 18.3 and 20.3 % lower cell viability at 6.25, 12.50 and 25.0 
µM respectively. To put these in vitro results into perspective, cell 
viability experiments were also performed using the commonly used 
pancreatic cancer antimetabolite drug 5-fluoruracil (5-FU). Both cell 
lines were treated with 5-FU at concentrations of 50, 100 and 250 µM 
and cell viability recorded 24 h later using the MTT assay. As shown 
in fig S9, the maximum reduction in cell viability observed was 
similar at 23 % and 26 % for MIA PaCa-2 and BxPC-3 respectively 
at 250 µM 5-FU. Therefore, these results confirm that PDT using 6a 
or 6b is significantly more effective than 5-FU at killing these 
pancreatic cancer cell lines.  
Based on its singlet oxygen generation and in vitro toxicity when 
compared to 6b, in addition to its inherent NIR fluorescence, 6a was 
selected as a candidate for in vivo studies. Ectopic BxPC-3 Luc 
pancreatic tumours were established in SCID mice and once the 
tumours had reached an average volume of 205 mm3, the mice were 
randomly separated into two groups. One group received no treatment 
(control) and one group received an intra-tumoural injection (2.5 
mg/kg) of 6a followed by 9 min exposure to 780 nm light (100 mW) 
with a 1 min lag after 3 and 6 min.  The latter group also received a 
second treatment at day 8.  The tumour volumes were monitored in 
each group and the results shown in Fig 2a reveal that by day 11, 
tumours in the untreated group had grown by almost 500 % from their 
pre-treatment value, while PDT treated tumours had increased in 
 
 
Scheme 1. Scheme 1   Synthetic scheme for preparation of 6a and 6b. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 Plot of cell viability for BxPC-3 cells (left panel) and MiaPaCa-2 cells 
(right panel) treated with ICG (a+d), 6a (b and e) and 6b (c and f) with (white 
bars) and without (black bars) 780 nm (100 mW) light treatment for 1 min. 
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volume by only 39 % over the same time period (p < 0.001). Indeed, 
4 days after PDT treatment, the tumours reduced from their pre-
treatment size by 10 %. Between days 4-7 the tumours gradually 
increased back to their pre-treatment values but following a second 
PDT treatment on day 8 they again reduced in volume until day 11, 
when the experiment was terminated due to the control tumours 
reaching their maximum permissible size.  
 In the above in vivo study, an intra-tumoral injection was used to 
preclude variables associated with systemic delivery and guarantee 
that a consistent dose of sensitiser was administered to each subject. 
In the clinic however, PDT treatment of pancreatic cancer requires 
intravenous (IV) administration of the sensitiser followed by 
ultrasound or MRI guided interstitial light treatment. We were 
therefore interested in examining the specificity of uptake of 6a by 
pancreatic tumours following IV administration.18 In addition, this 
experiment would also allow us to assess the potential of 6a as a real-
time NIR fluorescence imaging agent. A solution of 6a was 
administered by tail vein injection and imaged 18 h later using an IVIS 
whole body imaging system with images collected in the 
bioluminescence, fluorescence and overlay modes. The results are 
shown in fig 2b-e and reveal an intense NIR fluorescence signal from 
the tumour region with an almost identical overlap between the 
fluorescence of 6a and tumour bioluminescence signal. Indeed, there 
was no evidence of fluorescence in any other region 18h post 
administration illustrating effective uptake of 6a by the tumour and 
clearance from non-target tissue. While PDT is a targeted cancer 
treatment, it is still beneficial for the sensitiser to accumulate in the 
tumour to avoid collateral damage to surrounding healthy tissue in the 
event of misguided light treatment. This is particularly relevant in the 
treatment of pancreatic cancer where the tumour is often located close 
to critical anatomical structures such as veins or arteries and where 
inadvertent tissue damage could have serious consequences for the 
patient.  
In conclusion, we have demonstrated that the addition of iodine 
atoms to the basic structural skeleton of an NIR absorbing 
indocyanine dye, improves singlet oxygen production and enhances 
PDT mediated cytotoxicity when compared to the non-iodinated and 
clinically-approved analogue ICG. PDT treatment of mice bearing 
ectopic human xenograft BxPC-3 pancreatic tumours using 6a 
significantly reduced tumour burden and was sufficiently fluorescent 
to enable real-time NIR fluorescence imaging in vivo. Pancreatic 
cancer remains one of the most recalcitrant forms of the disease in 
which survival statistics haven’t changed in over 40 years, illustrating 
a clear unmet need for alternative approaches to treat the disease. NIR 
activated PDT using 6a may provide an alternative approach to 
conventional chemotherapy as a neo-adjuvant or palliative treatment 
for patients who present with locally advanced or metastatic disease. 
Since the latter represent over 70% of patients, such a treatment could 
find widespread appeal as a minimally invasive treatment with limited 
off-target side-effects.   
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Fig. 2 (a) Plot of tumour volume against time for SCID mice bearing ectopic 
BxPC3-Luc tumours following treatment with (squares) or without (circles) 
6a and 780 nm light (3 x 3 min). Arrow indicates 2nd treatment. *p ≤ 0.05; 
**p ≤ 0.01 and ***p ≤ 0.001. Whole body fluorescence (b and c), 
bioluminescence (d) and combined fluorescence / bioluminescence overlay 
image (e) of SCID mice bearing ectopic BxPC3-Luc tumours recorded before 
(b) and 18 h after (c-e) tail vein administration of 6a. Images f-g show 
bioluminescence (top) and fluorescence (bottom) of BxPC-3Luc tumours 
excised 18h after tail vein administration of vehicle only (f) or 6a (g).  
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